TCS, Oracle & DrugLogic prescribe safety in CapsuleTM

RELATED NEWS TCS wins outsourcing deal in Mexico, stock up Infosys, TCS hit 52-week lows TCS an underperformer, target price of Rs 1135: CLSA Fund Action: TCS, DLF, LIC Housing Finance ALSO READ See latest News about TCS See previous management interviews See what other Experts & Brokerages are saying about TCS TCS BSE | NSE 09/02/12 Are Mutual Funds betting on TCS?

Tata Consultancy Services (TCS), (BSE: TCS.BO, NSE: TCS.NS), a leading global IT services, business solutions and outsourcing firm and Certified Advantage Partner in the Oracle PartnerNetwork, announced its collaboration with Oracle and DrugLogic to deliver an integrated & comprehensive Drug Safety and Pharmacovigilance Solution - Safety in a Capsule^TM.

 

In recent years, pharmacovigilance and drug safety have received greater public and government scrutiny following a series of high-profile drug recalls and withdrawals. As a result, pharmaceutical manufacturers are more focused than ever on improving their ability to monitor and quickly identify adverse events. Safety in a Capsule^TM, a joint initiative of TCS, Oracle and DrugLogic, addresses this need with a pre-packaged safety offering that helps pharmaceutical manufacturers and biotech companies improve their ability to monitor events and ensure compliance with increasingly stringent regulatory requirements.

 

Safety in a Capsule^TM combines Oracle's Siebel Contact Center Integration Pack for Oracle Adverse Event Reporting System, DrugLogic's signal detection solution 'Qscan' and TCS' Knowledge Process Outsourcing (KPO) services to provide a cost-effective Drug Safety architecture for pro-active pharmacovigilance. TCS' KPO center in India provides clinical services for large pharmaceutical companies that include Clinical Data Management (CDM), Statistical Analysis (SA), Scientific Communication (SC) and Drug Safety and Pharmacovigilance services.

 

Safety in a Capsule^TM will streamline and monitor safety and surveillance processes followed by pharmaceutical and biotech companies during the lifecycle of a drug to minimize risks and costs. The solution will leverage safety analytics for early insight into a drug's safety profile and rapidly analyze patterns in adverse events that may indicate emerging drug safety risks pre- and post-market.

 

Mr. Rajagopal J, Executive Vice President and Global Head - Consulting; Life Sciences and Medical Devices Practice, TCS said, "Safety in a Capsule^TM is a pioneering effort by TCS and its partners to help pharmaceutical and biotech companies build a unified drug safety architecture. The solution will help improve drug safety, minimize risks and reduce costs while adhering to good pharmacovigilance practices.  Safety in a Capsule^TM is the result of TCS' focus on providing the best in class IT services, business solutions and outsourcing services to customers across the world."

 

"Pharmaceutical and biotech organizations often store relevant safety data in various information silos, precluding them from leveraging its full value. As such, integration and analytics capabilities are critical to helping pharmaceutical and biotech companies rapidly identify and assess potential safety issues," said Neil de Crescenzo, Group Vice President, Healthcare and Life Sciences, Oracle. "Safety in a Capsule^TM, which incorporates Oracle's Siebel Contact Center Integration Pack for Oracle Adverse Event Reporting System, provides a cost-effective architecture that enables the integration and analysis required to rapidly identify and act on emerging issues - ultimately advancing drug safety and compliance in a highly regulated industry."

 

"Integration of Oracle Adverse Event Reporting System, DrugLogic's Qscan®-ERM and TCS services provides complete safety signal detection and safety surveillance capabilities within a vendor-supported platform that is unparalleled in the life sciences industry," said Victor V. Gogolak, President of DrugLogic.  "Drug safety teams can monitor and analyze - in a single view - legacy, clinical and pre- and post-market adverse event data.  And most significantly, the validated applications meet regulatory requirements for safety and pharmacovigilance."

 

Sourced From: Vaishnavi Corporate Communications Pvt Ltd